TheraRadar
Data updated: Jun 28, 2026

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE (nicardipine hydrochloride) · Cipla

Cardiovascular Approved 2008-07-24

Nicardipine hydrochloride helps patients with high blood pressure and chronic stable angina, a condition involving chest pain during physical exertion. It is used as a standalone therapy or in combination with other medications, such as beta-blockers, to manage these cardiovascular conditions. When used to lower blood pressure, it is important to monitor the drug's effect throughout the dosing cycle due to potential differences in its impact between peak and trough levels.

How NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Works

This medication works by blocking the movement of calcium ions into cardiac and vascular smooth muscle cells through specific channels. By preventing this influx, the drug helps relax the smooth muscle in blood vessels, particularly those in the heart, with minimal impact on the heart's contraction strength. This selective relaxation of the vascular system helps improve blood flow and manage pressure.

3
Indications
--
Phase 3 Trials
17
Years on Market

Details

Status
Prescription
First Approved
2008-07-24
Routes
INTRAVENOUS
Dosage Forms
INJECTABLE

Companies

Active Ingredient: NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Approval History

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
26 FDA actions from 2008 to 2025
Oct 2025 ORIGINAL
Update
Jun 2025 SUPPL
Mfg · Manufacturing (CMC)
Mar 2025 SUPPL
Label · Labeling

What NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Treats

2 indications

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is approved for 2 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 12 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMLODIPINE BESYLATE AND VALSARTAN
AMLODIPINE BESYLATE
2 shared
HETERO LABS
Shared indications:
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
AMLODIPINE BESYLATE
2 shared
STRIDES PHARMA INTL
Shared indications:
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER
NICARDIPINE HYDROCHLORIDE
2 shared
CHIESI
Shared indications:

Cipla's other novel FDA approvals

Other CDER-designated drugs from the same sponsor (2016–2025).

📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT03098680 PRIME PRIME (A094136) Ph 1 terminated A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
NCT01810302 results posted 034-2013 Ph 2 terminated Safety Study of Nicardipine to Treat Cerebral Vasospasm
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE FDA Label Details

Indications & Usage

FDA Label (PDF)

I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). Nicardipine hydrochloride capsules may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. Nicardipine hydrochloride capsules may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect (Se...

Track NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.